SGO/ACCC Joint Education Collaborative: Optimizing Outcomes in Ovarian Cancer Using Personalized Medicine

Executive summary

The Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC) have been awarded a joint independent medical education grant from AstraZeneca and Merck. Together, SGO and ACCC will offer four accredited webinars (live and enduring) and up to six additional non-accredited media presentations (podcasts, clinical reviews) on the topic of delivering personalized medicine in a community setting. The webinar/virtual media programs are expected to launch in June 2021 and offered on a monthly rotation over the course of the year.

LATEST CONTENT –

JUNE

“Conversations in the Clinic: Patient Perspectives on Genetic Testing” Podcast
Listeners will learn about the importance of genetic testing for ovarian cancer from a genetic counselor and a physician, and most importantly, from a patient.

Moderator: Ashley Stuckey, MD
Speakers: Todd Tillmanns, MD, FACOG, West Cancer Center and Leigha Senter-Jamieson, MS, LGC, The Ohio State University Wexner Medical Center

July

Genetic Testing FAQ Sheet
Coming Soon!

Steering committee –

William Burke, MD, Stony Brook University Cancer Center	Melissa Hardesty, MD, MPH, Alaska Women’s Cancer Care
Premal Thaker, MD, MS, Washington University in St. Louis, Siteman Cancer Center	Ashley Stuckey, MD Brown University, Women and Infants Hospital
Todd Tillmanns, MD, FACOG, West Cancer Center	Jeff Lin, MD, City of Hope Medical Group
Roisin O’Cearbhaill, MD, Memorial Sloan Kettering Cancer Center	Charles Drescher, MD, Swedish Cancer Institute
John Farley, MD, COL, FACOG, FACS, Dignity Health Cancer Institute, St. Joseph’s Hospital and Medical Center	Leigha Senter-Jamieson, MS, LGC, The Ohio State University Wexner Medical Center

Target Audience

The target audience for this initiative includes medical oncologists, gynecologic oncologists, obstetrician-gynecologists, primary care physicians, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, pathologists, and other healthcare professionals (HCPs) involved in treating patients with ovarian cancer.

Learning Objectives

At the end of this educational initiative, participants should be able to:

Discuss the utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer
Assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling in patients with ovarian cancer
Implement monitoring strategies and manage adverse events of emerging targeted therapies for patients with ovarian cancer
Explore strategies to improve patient engagement in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer along the continuum of care

Accreditations

The live/online webinars will each offer the following credits:

CME: 0.5 AMA PRA Category 1 Credit(s)™
ACPE credit: 0.5 contact hour
ANCC credit: 0.5 contact hour

Non-accredited educational materials: podcasts, case reviews, and other educational resources/tools

Evaluation and Outcomes

The impact of participating in this initiative on clinical performance related to the optimal management of ovarian cancer will be assessed by comparing the response for pre-activity and post-activity tests (also designed by the Steering Committee). The outcomes analysis will assess the effectiveness of the programs in changing knowledge and competence, and intent to change behavior among learners in the following areas:

Learners will have a better understanding of utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer
Learners will correctly assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling for therapeutic implications in ovarian cancer patients
Learners will be better prepared to monitor and manage adverse events for emerging targeted therapies for patients with and ovarian cancer
Learners will be more familiar with implementing strategies to improve engage patients in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer throughout the continuum of care starting at diagnosis

Advertise With Us

Join SGO Today

What you get out of membership changes your patient’s lives. What you give from your membership changes the world. Join your community today.

Become a Member

Educational materials that are part of accredited education (such as slides, abstracts, handouts, evaluation mechanisms, or disclosure information) must not contain any marketing produced by or for an ineligible company, including corporate or product logos, trade names, or product group messages. This activity has been supported by an independent medical education grant from AstraZeneca and Merck.

Collaborations